Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample by Semmler, Alexander et al.
ORIGINAL COMMUNICATION
Genetic variants of methionine metabolism and X-ALD phenotype
generation: results of a new study sample
Alexander Semmler Æ Xinhua Bao Æ Guangna Cao Æ
Wolfgang Ko¨hler Æ Michael Weller Æ
Patrick Aubourg Æ Michael Linnebank
Received: 2 October 2008 / Revised: 18 February 2009 / Accepted: 17 March 2009 / Published online: 8 April 2009
 Springer-Verlag 2009
Abstract X-linked adrenoleukodystrophy (X-ALD) is the
most common inherited leukodystrophy. Nevertheless,
no genotype–phenotype correlation has been established
so far. Unidentified modifier genes or other cofactors are sus-
pected to modulate phenotype and prognosis. We recently
described polymorphisms of methionine metabolism as pos-
sible disease modifiers in X-ALD. To retest these findings, we
analyzed 172 new DNA samples of X-ALD patients from
different populations (France, Germany, USA, China) by
genotyping eight genetic variants of methionine metabolism,
including DHFR c.594?59del19bp, CBS c.844_855ins68,
MTR c.2756A[G, MTHFR c.677C[T and c.1298A[C,
MTRR c.60A[G, RFC1 c.80G[A, and Tc2 c.776C[G. We
compared three X-ALD phenotypes: childhood-onset cere-
bral demyelinating inflammatory type (CCALD; n = 82),
adulthood onset with focal cerebral demyelination
(ACALD; n = 38), and adulthood onset without cerebral
demyelination (AMN; n = 52). The association of geno-
types and phenotypes was analyzed with univariate two-
sided Pearson’s v2. In the comparison between AMN and
CCALD, the G allele of Tc2 c.776C[G was associated
with X-ALD phenotypes (v2 = 6.1; P = 0.048). The
prevalence of the GG genotype of Tc2 c.776C[G was
higher in patients with CNS demyelination compared to
those without CNS demyelination (v2 = 4.42; P = 0.036).
The GG genotype was also more frequent in CCALD
compared to AMN (v2 = 4.7; P = 0.031). The other
polymorphisms did not show any significant associations in
this study sample. Whereas the influence of other poly-
morphisms of methionine metabolism was not confirmed,
the present study supports the previously made observation
that the Tc2 genotype contributes to X-ALD phenotype
generation.
Keywords Leukoencephalopathy  Neurogenetics 
Association studies in genetics  Leukodystrophies 
Peroxisomes  Metabolic disease (inherited)
Introduction
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100)
is caused by defects of the ABCD1 gene on chromosome
Xq28, resulting in an impairment of peroxisomal beta
oxidation and the accumulation of saturated very long
chain fatty acids (VLCFA). The minimum frequency of
hemizygotes plus heterozygotes is 1:16,800 in the United
States, suggesting that X-ALD is the most common
inherited leukodystrophy [3].
Alexander Semmler and Xinhua Bao contributed equally to this work.
A. Semmler  M. Weller
Department of Neurology, University Hospital Zu¨rich, Zu¨rich,
Switzerland
X. Bao  G. Cao
Department of Pediatrics, First Hospital, Peking University,
Peking, China
W. Ko¨hler
Department of Neurology, Sa¨chsisches Krankenhaus
Hubertusburg, Wermsdorf, Germany
P. Aubourg
INSERM U745, Department of Pediatric Neurology, Hoˆpital
Saint-Vincent de Paul, University Rene´ Descartes, Paris, France
M. Linnebank (&)
Department of Neurology, University of Zu¨rich,
Frauenklinikstrasse 26, 8091 Zu¨rich, Switzerland
e-mail: michael.linnebank@usz.ch
123
J Neurol (2009) 256:1277–1280
DOI 10.1007/s00415-009-5114-6
X-ALD is characterized by a highly variable clinical
spectrum. It ranges from cerebral demyelinating, inflam-
matory childhood phenotypes associated with a poor
prognosis (CCALD), to milder adulthood disease with
focal demyelination in the central nervous system
(ACALD), to adulthood forms without central nervous
system demyelination and considerably slower symptom
progression (AMN). The appearance of cerebral demye-
lination is crucial to the phenotype and prognosis of X-
ALD as well as therapy for it. The development of the
phenotype cannot be predicted by biochemical factors like
levels of VLCFA. In addition, no genotype/phenotype
correlation has been established [13]. The clinical course
can range widely, even within closely related patients.
Thus, as yet unidentified modifier genes or other cofactors
are likely to modulate the phenotypic variation and disease
severity [5–8].
One possible X-ALD disease modifier may be methionine
metabolism. Methionine metabolism plays a crucial role in
DNA methylation and in providing methyl groups necessary
for building brain myelination. It is also involved in the gen-
eration of glutathione that is necessary for defense against
oxidative stress and in the regulation of inflammatory pro-
cesses [15]. The metabolism exhibits marked interindividual
variety due to the existence of functionally relevant poly-
morphisms and differences in vitamin availability, which are
important cofactors in methionine metabolism (vitamin B12,
B6, folic acid). We have previously reported that polymor-
phisms of methionine metabolism are associated with the
clinical phenotype of X-ALD. The insertion allele of cysta-
thionine beta-synthase (CBS) c.844_845ins68 was signifi-
cantly more common in AMN patients than in the cerebral
demyelinating forms CCALD and ACALD in a sample of 86
Dutch and German patients [12]. In addition to that, the GG
genotype of transcobalamin 2 (Tc2) c.776C[G was more
common in ACALD than in AMN, and a combined risk
genotype was more common in ACALD than in AMN. The
combined risk genotype was defined as the presence of at
least one of the following genotypes: transcobalamin 2
(Tc2) c.776C[G (GG), methylenetetrahydrofolate reductase
(MTHFR) c.677C[T (TT), or methionine synthase (MTR)
c.2756A[G (AG/GG) [9]. Here we studied the genotypes of
172 additional X-ALD patients to retest our previous data.
Materials and methods
Patients
We analyzed 172 DNA samples: 34 DNA samples from
China (CCALD: n = 21; ACALD: n = 9; AMN: n = 4),
110 samples from France (CCALD: n = 50; ACALD:
n = 25; AMN: n = 35), 8 DNA samples from Germany
(ACALD: n = 4; AMN: n = 4), and 20 samples from
the USA (CCALD: n = 11; AMN: n = 9). Patients
from China were of Han ethnicity; patients from France,
Germany and USA were of Caucasian origin. All patients
or their trustees have given written informed consent. The
study was approved by the local ethical committees.
Genotyping
Genomic DNA prepared from peripheral leukocytes was used
for genotyping by PCR amplification and restriction analysis
of eight genetic variants of methionine metabolism, including
the intronic deletion dihydrofolate reductase (DHFR)
c.594?59del19bp (affecting the transcript level; GenBank
NM_000791.3), the splice alteration cystathionine beta-syn-
thase (CBS) c.844_855ins68 (affecting the transcript level;
GenBank S78267.1), and the missense mutations (i.e., leading
to amino acid exchanges) methionine synthase (MTR)
c.2756A[G (p.D919G; rs1805087), methylenetetrahy-
drofolate reductase (MTHFR) c.677C[T (p.A222V;
rs1801133) and c.1298A[C (p.E429A; rs1801131), methio-
nine synthase reductase MTRR c.60A[G (p.I49M), reduced
folate carrier 1 (RFC1) c.80G[A (p.R27H; rs1051266), and
transcobalamin 2 (Tc2) c.776C[G (p.P259R; rs1801198)
[10].
Statistics
The association of genotypes and phenotypes was analyzed
with univariate two-sided Pearson’s v2 tests. As this is a
confirmatory study, we did not correct for multiple testing.
Results
Analyses with two degrees of freedom (all genotypes)
revealed an association of the G allele of Tc2 c.776C[G
with the X-ALD phenotype in the comparison between
AMN and CCALD (v2 = 6.09; P = 0.048), but not in the
comparison between AMN and the pooled demyelinating
phenotypes CCALD?ACALD, v2 = 4.74; P = 0.093. The
other polymorphisms did not reveal significant associations
in this study sample (Table 1). When only the Caucasian
patients without the patients from China or subgroups
divided by populations were analyzed, the differences in
the frequencies of the Tc2 genotype among different
X-ALD phenotypes were not significant (not shown). The
prevalence of the GG genotype of Tc2 c.776C[G was
higher in patients with CNS demyelination than in those
without CNS demyelination (v2 = 4.42; P = 0.036).
Additionally, the GG genotype was more frequent in
patients with the most severe phenotype, CCALD, than in
patients with AMN (v2 = 4.71; P = 0.031) (Table 2).
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Discussion
In the present study consisting of 172 patients with CCALD,
ACALD and AMN, we found that the G allele of the Tc2
c.776C[G polymorphism is associated with the occurrence of
CNS demyelination in X-ALD patients. The G allele of Tc2
c.776C[G leads to the amino acid substitution p.P259R that
seems to affect the affinity of the transcobalamin 2 protein to
vitamin B12 and the ability to transport vitamin B12 into
tissues [1, 2, 4]. Vitamin B12 is necessary to synthesize S-
adenosylmethionine, which serves as methyl group donor for
CNS myelination. Accordingly, vitamin B12 deficiency can
lead to demyelination of the central nervous system in
otherwise healthy individuals [16].
Methotrexate is a widely used chemotherapeutic drug
that may lead to neurotoxic side effects accompanied by
cerebral white matter changes. Methotrexate reduces the
vitamin B12-dependent synthesis of S-adenosylmethionine
Table 1 Result of all polymorphisms analyzed and X-ALD phenotypes: CCALD (n = 82), ACALD (n = 38), and AMN (n = 52)
Tc2 c.776C[G CC CG GG CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.19 0.42 0.39 P = 0.048 P = 0.093
ACALD 0.34 0.32 0.34
AMN 0.35 0.44 0.21
MTR c.2756A[G AA AG GG CCALD vs. AMN CCALD/ACALD vs. AMN
CCALD 0.72 0.25 0.03 P = 0.364 P = 0.393
ACALD 0.78 0.22 0
AMN 0.69 0.31 0
MTHFR c.677C[T CC CT TT CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.42 0.39 0.19 P = 0.940 P = 0.970
ACALD 0.31 0.53 0.16
AMN 0.40 0.42 0.18
MTHFR c.1298A[C AA AC CC CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.59 0.33 0.08 P = 0.721 P = 0.964
ACALD 0.42 0.53 0.05
AMN 0.51 0.41 0.08
CBS c.844_845ins68 dd di ii CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.89 0.11 0 P = 0.659 P = 0.989
ACALD 0.89 0.11 0
AMN 0.89 0.11 0
MTRR c.60A[G AA AG GG CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.14 0.42 0.44 P = 0.226 P = 0.502
ACALD 0.24 0.54 0.22
AMN 0.15 0.57 0.28
RFC1 c.80G[A GG AG AA CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.31 0.47 0.22 P = 0.948 P = 0.822
ACALD 0.27 0.43 0.30
AMN 0.33 0.46 0.21
DHFR c.594?59del19bp dd di ii CCALD vs. AMN CCALD?ACALD vs. AMN
CCALD 0.14 0.51 0.35 P = 0.253 P = 0.238
ACALD 0.12 0.54 0.34
AMN 0.06 0.48 0.46
Table 2 Tc2 c.776-GG genotype and X-ALD phenotypes: CCALD (n = 82), ACALD (n = 38), and AMN (n = 52)
Tc2 c.776C [ G CC/CG GG Pure AMN vs. CCALD Pure AMN vs. CCALD ? ALMN
CCALD 0.61 0.39 P = 0.031 P = 0.036
ACALD 0.66 0.34
AMN 0.79 0.21
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in the central nervous system [14]. In a series of 68 patients
treated with methotrexate, the G allele and the GG geno-
type of Tc2 c.776C[G were associated with the occurrence
of white matter changes in the brain [11]. We conclude that
it is unlikely that the GG genotype of Tc2 c.776C[G is the
main determinant of the different X-ALD phenotypes, but
this observation may serve as an indicator of a role of the
methionine metabolism in X-ALD disease progression in
general. We speculate that the influence of the GG geno-
type of Tc2 c.776C[G on the functional availability of
vitamin B12 and SAM synthesis may dispose X-ALD
patients to demyelination of the central nervous system.
In a previous study with a sample of 86 Dutch and
German patients, we observed an association of X-ALD
phenotypes with additional genetic variants of the methi-
onine metabolism [9, 12]. In the actual sample we only
confirmed the association of the G allele of the polymor-
phism Tc2 c.776C[G with the occurrence of CNS demy-
elination in X-ALD patients, whereas the other previous
observations were not confirmed. We cannot completely
exclude differences between the previous and the actual
patient samples that might have contributed to the differ-
ences in the results. Dietary influences concerning the
uptake of amino acids or vitamins may speculatively
modify effects of the analyzed polymorphisms on X-ALD
phenotype generation, and dietary conditions might have
differed between the old and the new patient sample.
However, we conclude that only the influence of the Tc2
polymorphism is validated by the results of the present
study, whereas the other previously reported findings must
be assumed to be false positives so long as they are not
confirmed in an additional X-ALD patient sample.
These data are limited, as the association is only weakly
significant. When corrected for multiple testing or analyzed
in subgroups divided up by populations or ethnicity, the
results were not significant. However, this study was of a
confirmative nature, and as the results concerning the Tc2
variant confirmed our previous observations in an inde-
pendent sample of X-ALD patients, we consider the
influence of the Tc2 c.776C[G variant on phenotype
generation in X-ALD to be confirmed.
An examination of the effect of experimentally induced
vitamin B12, folate and SAM depletion in addition to
vitamin B12, folate and SAM substitution on the phenotype
of X-ALD mouse models appears to be warranted in order
to estimate whether clinical studies investigating the effect
of vitamin or SAM substitution on the clinical course of
X-ALD are justified.
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